Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone

Mathieu Garand, Joellen H.H. Lin, Branislava Zagorac, Marlys L. Koschinsky, Michael B. Boffa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-carboxypeptidase B-like pro-enzyme that upon activation attenuates fibrinolysis and inflammatory processes. There is a large inter-individual variability in plasma TAFI levels within the population which is primarily due to epigenetic factors. Novel associations between plasma TAFI levels and sex steroids have triggered interest in determining the role of TAFI as a mediator of the cardioprotective effects of estrogens and progestins, or as a mediator of the increased thrombotic risk that accompanies use of oral contraceptives or hormone replacement therapy (HRT). In this study, we measured the effect of sex steroids on hepatic expression of CPB2, the human gene encoding TAFI. Using human hepatocellular carcinoma cells cultured in the presence of progesterone and 17β-estradiol, we demonstrated that the level of TAFI protein is decreased by those sex steroids. These changes in protein expression were paralleled by decreases in CPB2 mRNA abundance and promoter activity. We did not find evidence of estrogen or progesterone receptor binding sites in the CPB2 promoter region, suggesting that the genomic effects of progesterone and 17β-estradiol are mediated indirectly, without receptor binding to the CPB2 promoter. Indeed, we found that the effect of estrogen was independent of the estrogen receptor and was mediated through a novel signaling pathway dependent on phosphatidylinositol 3-kinase and Akt that did not involve GPR30. Our findings provide the molecular explanation for the ability of female sex steroids to decrease plasma TAFI concentrations.

Original languageEnglish
Pages (from-to)393-404
Number of pages12
JournalBlood Coagulation and Fibrinolysis
Volume24
Issue number4
DOIs
Publication statusPublished - 1 Jun 2013
Externally publishedYes

Fingerprint

Carboxypeptidase B2
Progesterone
Estrogens
Genes
Steroids
Estrogen Receptors
Estradiol
Carboxypeptidase B
Phosphatidylinositol 3-Kinase
Enzyme Activation
Hormone Replacement Therapy
Fibrinolysis
Progestins
Progesterone Receptors
Oral Contraceptives
Genetic Promoter Regions
Epigenomics
Hepatocellular Carcinoma
Cultured Cells
Proteins

Keywords

  • Akt
  • estrogen
  • progesterone
  • thrombin-activatable fibrinolysis inhibitor
  • thrombosis
  • transcription

ASJC Scopus subject areas

  • Hematology

Cite this

Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. / Garand, Mathieu; Lin, Joellen H.H.; Zagorac, Branislava; Koschinsky, Marlys L.; Boffa, Michael B.

In: Blood Coagulation and Fibrinolysis, Vol. 24, No. 4, 01.06.2013, p. 393-404.

Research output: Contribution to journalArticle

Garand, Mathieu ; Lin, Joellen H.H. ; Zagorac, Branislava ; Koschinsky, Marlys L. ; Boffa, Michael B. / Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. In: Blood Coagulation and Fibrinolysis. 2013 ; Vol. 24, No. 4. pp. 393-404.
@article{4ecb891f5ee840afae2772376c121cb8,
title = "Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone",
abstract = "Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-carboxypeptidase B-like pro-enzyme that upon activation attenuates fibrinolysis and inflammatory processes. There is a large inter-individual variability in plasma TAFI levels within the population which is primarily due to epigenetic factors. Novel associations between plasma TAFI levels and sex steroids have triggered interest in determining the role of TAFI as a mediator of the cardioprotective effects of estrogens and progestins, or as a mediator of the increased thrombotic risk that accompanies use of oral contraceptives or hormone replacement therapy (HRT). In this study, we measured the effect of sex steroids on hepatic expression of CPB2, the human gene encoding TAFI. Using human hepatocellular carcinoma cells cultured in the presence of progesterone and 17β-estradiol, we demonstrated that the level of TAFI protein is decreased by those sex steroids. These changes in protein expression were paralleled by decreases in CPB2 mRNA abundance and promoter activity. We did not find evidence of estrogen or progesterone receptor binding sites in the CPB2 promoter region, suggesting that the genomic effects of progesterone and 17β-estradiol are mediated indirectly, without receptor binding to the CPB2 promoter. Indeed, we found that the effect of estrogen was independent of the estrogen receptor and was mediated through a novel signaling pathway dependent on phosphatidylinositol 3-kinase and Akt that did not involve GPR30. Our findings provide the molecular explanation for the ability of female sex steroids to decrease plasma TAFI concentrations.",
keywords = "Akt, estrogen, progesterone, thrombin-activatable fibrinolysis inhibitor, thrombosis, transcription",
author = "Mathieu Garand and Lin, {Joellen H.H.} and Branislava Zagorac and Koschinsky, {Marlys L.} and Boffa, {Michael B.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1097/MBC.0b013e32835d543a",
language = "English",
volume = "24",
pages = "393--404",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone

AU - Garand, Mathieu

AU - Lin, Joellen H.H.

AU - Zagorac, Branislava

AU - Koschinsky, Marlys L.

AU - Boffa, Michael B.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-carboxypeptidase B-like pro-enzyme that upon activation attenuates fibrinolysis and inflammatory processes. There is a large inter-individual variability in plasma TAFI levels within the population which is primarily due to epigenetic factors. Novel associations between plasma TAFI levels and sex steroids have triggered interest in determining the role of TAFI as a mediator of the cardioprotective effects of estrogens and progestins, or as a mediator of the increased thrombotic risk that accompanies use of oral contraceptives or hormone replacement therapy (HRT). In this study, we measured the effect of sex steroids on hepatic expression of CPB2, the human gene encoding TAFI. Using human hepatocellular carcinoma cells cultured in the presence of progesterone and 17β-estradiol, we demonstrated that the level of TAFI protein is decreased by those sex steroids. These changes in protein expression were paralleled by decreases in CPB2 mRNA abundance and promoter activity. We did not find evidence of estrogen or progesterone receptor binding sites in the CPB2 promoter region, suggesting that the genomic effects of progesterone and 17β-estradiol are mediated indirectly, without receptor binding to the CPB2 promoter. Indeed, we found that the effect of estrogen was independent of the estrogen receptor and was mediated through a novel signaling pathway dependent on phosphatidylinositol 3-kinase and Akt that did not involve GPR30. Our findings provide the molecular explanation for the ability of female sex steroids to decrease plasma TAFI concentrations.

AB - Thrombin-activatable fibrinolysis inhibitor (TAFI) is a pro-carboxypeptidase B-like pro-enzyme that upon activation attenuates fibrinolysis and inflammatory processes. There is a large inter-individual variability in plasma TAFI levels within the population which is primarily due to epigenetic factors. Novel associations between plasma TAFI levels and sex steroids have triggered interest in determining the role of TAFI as a mediator of the cardioprotective effects of estrogens and progestins, or as a mediator of the increased thrombotic risk that accompanies use of oral contraceptives or hormone replacement therapy (HRT). In this study, we measured the effect of sex steroids on hepatic expression of CPB2, the human gene encoding TAFI. Using human hepatocellular carcinoma cells cultured in the presence of progesterone and 17β-estradiol, we demonstrated that the level of TAFI protein is decreased by those sex steroids. These changes in protein expression were paralleled by decreases in CPB2 mRNA abundance and promoter activity. We did not find evidence of estrogen or progesterone receptor binding sites in the CPB2 promoter region, suggesting that the genomic effects of progesterone and 17β-estradiol are mediated indirectly, without receptor binding to the CPB2 promoter. Indeed, we found that the effect of estrogen was independent of the estrogen receptor and was mediated through a novel signaling pathway dependent on phosphatidylinositol 3-kinase and Akt that did not involve GPR30. Our findings provide the molecular explanation for the ability of female sex steroids to decrease plasma TAFI concentrations.

KW - Akt

KW - estrogen

KW - progesterone

KW - thrombin-activatable fibrinolysis inhibitor

KW - thrombosis

KW - transcription

UR - http://www.scopus.com/inward/record.url?scp=84877718815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877718815&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e32835d543a

DO - 10.1097/MBC.0b013e32835d543a

M3 - Article

VL - 24

SP - 393

EP - 404

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 4

ER -